中华内分泌代谢杂志
中華內分泌代謝雜誌
중화내분비대사잡지
CHINESE JOURNAL OF ENDOCRINOLOGY AND METABOLISM
2014年
3期
218-220
,共3页
叶小珍%刘隽%王扬天%张敏娟%王坚
葉小珍%劉雋%王颺天%張敏娟%王堅
협소진%류준%왕양천%장민연%왕견
氧化应激%氧化应激DNA损伤%血清8-OHdG水平%格雷夫斯眼病%糖皮质激素
氧化應激%氧化應激DNA損傷%血清8-OHdG水平%格雷伕斯眼病%糖皮質激素
양화응격%양화응격DNA손상%혈청8-OHdG수평%격뢰부사안병%당피질격소
Oxidative stress%Oxidative DNA damage%8-hydroxy-deoxyguanosine%Graves' ophthalmopathy%Corticosteroid
探讨氧化应激DNA损伤水平在活动性Graves眼病(Graves' ophthalmopathy,GO)患者经糖皮质激素治疗后的变化情况.与对照组和Graves病(GD)组相比,GO组的血清8-羟基脱氧鸟嘌呤(8-hydroxy-deoxyguanosine,8-OHdG)显著增高(P<0.05);GO患者经糖皮质激素治疗后血清8-OHdG水平及临床疾病活动分数(clinical activity score)较治疗前显著降低(P<0.05);治疗后的血清8-OHdG水平低于GD组(P<0.05).氧化应激参与GO的发病,GO患者的血清8-OHdG水平经糖皮质激素治疗后明显下降,可作为判断GO治疗效果的良好指标.
探討氧化應激DNA損傷水平在活動性Graves眼病(Graves' ophthalmopathy,GO)患者經糖皮質激素治療後的變化情況.與對照組和Graves病(GD)組相比,GO組的血清8-羥基脫氧鳥嘌呤(8-hydroxy-deoxyguanosine,8-OHdG)顯著增高(P<0.05);GO患者經糖皮質激素治療後血清8-OHdG水平及臨床疾病活動分數(clinical activity score)較治療前顯著降低(P<0.05);治療後的血清8-OHdG水平低于GD組(P<0.05).氧化應激參與GO的髮病,GO患者的血清8-OHdG水平經糖皮質激素治療後明顯下降,可作為判斷GO治療效果的良好指標.
탐토양화응격DNA손상수평재활동성Graves안병(Graves' ophthalmopathy,GO)환자경당피질격소치료후적변화정황.여대조조화Graves병(GD)조상비,GO조적혈청8-간기탈양조표령(8-hydroxy-deoxyguanosine,8-OHdG)현저증고(P<0.05);GO환자경당피질격소치료후혈청8-OHdG수평급림상질병활동분수(clinical activity score)교치료전현저강저(P<0.05);치료후적혈청8-OHdG수평저우GD조(P<0.05).양화응격삼여GO적발병,GO환자적혈청8-OHdG수평경당피질격소치료후명현하강,가작위판단GO치료효과적량호지표.
The change in serum level of 8-hydroxy-deoxyguanosine (8-OHdG),an oxidative stress biomarker,in patients with active Graves' ophthalmopathy (GO) during corticosteroid treatment was observed.The serum level of 8-OHdG was significantly increased in patients with active GO as compared with that of normal controls and patients with Graves' disease (P < 0.05).After systemic corticosteroid treatment,patients with GO showed significantly lowered 8-OHdG level as compared with that before treatment and patients with Graves' disease.These changes in serum 8-OHdG level were accompanied by decreases in clinical activity score (P < 0.05) during corticosteroid treatment.Oxidative stress may play a role in the pathogenesis of GO.Serum 8-OHdG level may be used as an objective and quantitative parameter in patients with GO during immunosuppressive treatment.